Please assess the completion status of the following clinical trial:

Trial Title: Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Recent ESUS (between 7 days and 6 months), defined as:~* Recent ischemic stroke (including transient ischemic attack with positive neuroimaging) visualized by brain imaging that is not lacunar, and~* Absence of cervical carotid atherosclerotic stenosis\> 50% or occlusion, and~* No atrial fibrillation after ≥ 24-hour cardiac rhythm monitoring, and~* No intra-cardiac thrombus on either transesophageal or transthoracic echocardiography, and~* No other specific cause of stroke (for example, arteritis, dissection, migraine/vasospasm, drug abuse)~Exclusion Criteria:~* Severely disabling stroke (modified Rankin score ≥4)~* Indication for chronic anticoagulation or antiplatelet therapy~* Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m\^2

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban (Type: EXPERIMENTAL): Rivaroxaban 15 mg orally once daily
- Aspirin (Type: ACTIVE_COMPARATOR): Aspirin 100 mg orally once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).